Indaptus Therapeutics, Inc. (INDP) shareholders
Close on Nov 13, 2026Market cap $422.38MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Yao Yun | 41,991,000 | 27.34% | 13D (active) amendment | Oct 16, 2026 |
| Chenhao Xu Joint filing with Sino Lion Ventures Ltd (29.19%) | 38,895,000 | 29.19% | 13D (active) amendment | Jun 24, 2026 |
| Sino Lion Ventures Ltd Joint filing with Chenhao Xu (25.32%) | 38,895,000 | 25.32% | 13D (active) amendment | Oct 16, 2026 |
| Dai Junyi | 11,250,000 | 7.33% | 13D (active) amendment | Oct 16, 2026 |
| Yang Ting | 9,948,173 | 6.48% | 13D (active) amendment | Oct 16, 2026 |
| Lazar David E. | 2,064,000 | 47.93% | 13D (active) amendment | Mar 23, 2026 |
| YA II PN, Ltd. Joint filing with YA Global Investments II (U.S.), LP (9.99%), Yorkville Advisors Global, LP (9.99%) and 5 more | 1,410,916 | 9.99% | 13G (passive) | Feb 13, 2025 |
| Jeffery A. Meckler | 273,103 | 12.70% | 13D (active) amendment | Dec 22, 2025 |
| Newman Michael James | 115,552 | 5.40% | 13D (active) amendment | Dec 22, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INDP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 206,077 | 0.15% | $618.00K | New | 0.00% |
| Geode Capital Management, LLC | 56,470 | 0.04% | $169.41K | +29,463 | 0.00% |
| Jane Street Group, LLC | 53,811 | 0.04% | $161.43K | New | 0.00% |
| Vanguard Capital Management LLC | 33,652 | 0.03% | $100.96K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 13,967 | 0.01% | $41.90K | New | 0.00% |
| Millennium Management LLC | 11,586 | 0.01% | $34.76K | New | 0.00% |
| Morgan Stanley | 8,936 | 0.01% | $26.81K | +6,239 | 0.00% |
| UBS Group AG | 478 | 0.00% | $1.43K | New | 0.00% |
| SBI Securities Co., Ltd. | 17 | 0.00% | $51 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 9 | 0M | 0.3% | 6 / 2 | 0 / 2 | 0M | 0M |
| Q1 2026 | 6 | 0M | 0.1% | 4 / 0 | 1 / 2 | 0M | 0M |
| Q4 2025 | 4 | 0M | 0.0% | 0 / 2 | 1 / 1 | 0M | 0M |
| Q3 2025 | 5 | 0M | 0.0% | 2 / 2 | 1 / 2 | 0M | 0M |
| Q2 2025 | 5 | 0M | 0.0% | 1 / 1 | 2 / 15 | 0M | 0M |
| Q1 2025 | 19 | 0M | 0.0% | 1 / 5 | 3 / 2 | 0M | 0M |
| Q4 2024 | 20 | 0M | 0.0% | 3 / 4 | 3 / 1 | 0M | 0M |
| Q3 2024 | 18 | 0M | 0.0% | 1 / 3 | 4 / 4 | 0M | 0M |
| Q2 2024 | 21 | 0M | 0.0% | 5 / 3 | 4 / 1 | 0M | 0M |
| Q1 2024 | 17 | 0M | 0.0% | 1 / 2 | 5 / 3 | 0M | 0M |
| Q4 2023 | 19 | 0M | 0.0% | 3 / 5 | 1 / 0 | 0M | 0M |
| Q3 2023 | 16 | 0M | 0.0% | 2 / 4 | 4 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held INDP in Q2 2026, 29% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of INDP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 17,640 | 0.01% | $31.05K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 9,142 | 0.01% | $27.43K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 3,929 | 0.00% | $6.92K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 462 | 0.00% | $813 | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jeffrey A. Meckler | Co-Chief Executive Officer, Director | 229,929 | 0.17% | Feb 13, 2026 |
| Michael James Newman | CSO and Director | 1,469,430 | 1.10% | Dec 29, 2025 |
| Junyi Dai | Chief Executive Officer | 11,250,000 | 8.44% | Apr 2, 2026 |
| Walt Addison Linscott | Chief Operating Officer | 54,426 | 0.04% | Dec 29, 2025 |
| Nir Sassi | Chief Financial Officer | 26,758 | 0.02% | Dec 29, 2025 |
| Qinglai Lu | Director | – | – | Apr 20, 2026 |
| David E. Lazar | Director | 0 | – | Mar 24, 2026 |
| Jerome D. Jabbour | Director | – | – | Feb 27, 2026 |
| Matthew Charles McMurdo | Director | 25,000 | 0.02% | Feb 26, 2026 |
| Avraham Ben-Tzvi | Director | 25,100 | 0.02% | Jan 22, 2026 |
| David Natan | Director | 0 | – | Jan 22, 2026 |
| Hila Karah | Director | – | – | Jun 11, 2025 |
| Mark John Gilbert | Director | – | – | Jun 11, 2025 |
| Anthony J. Maddaluna | Director | 670 | 0.00% | Jun 11, 2025 |
| Roger Pomerantz | Director | – | – | Jun 11, 2025 |
| Robert Martell | Director | – | – | Jun 11, 2025 |
| William B. Hayes | Director | – | – | Jun 11, 2025 |
| LION VENTURES Ltd SINO | 10% owner | 38,895,000 | 29.19% | Apr 2, 2026 |
| Yun Yao | 10% owner | 41,991,000 | 31.51% | Apr 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Avraham Ben-Tzvi Director | Jan 20, 2026 | Award | +25,000 | – | – | 25,100 |
| Michael James Newman CSO and Director | Dec 22, 2025 | Award | +52,204 | $2.03 | $105.97K | 101,074 |
| Walt Addison Linscott Chief Operating Officer | Dec 22, 2025 | Award | +54,421 | $2.03 | $110.47K | 54,426 |
| Jeffrey A. Meckler Co-Chief Executive Officer, Director, 10% owner | Dec 22, 2025 | Award | +216,617 | $2.03 | $439.73K | 229,929 |
| Nir Sassi Chief Financial Officer | Dec 22, 2025 | Award | +26,758 | $2.03 | $54.32K | 26,758 |
| Jeffrey A. Meckler Chief Executive Officer, Director | Jul 27, 2025 | Award | +6,068 | $8.30 | $50.36K | 13,312 |
| Jeffrey A. Meckler CEO and Director | Nov 25, 2024 | Award | +42,553 | $1.18 | $50.21K | 202,859 |
| Jeffrey A. Meckler CEO and Director | Aug 8, 2024 | Award | +84,932 | $1.83 | $155.43K | 160,306 |
| Glen R. Anderson 10% owner | Aug 14, 2023 | Buy | +23,934 | $2.34 | $56.01K | 1,190,400 |
| Glen R. Anderson 10% owner | Aug 11, 2023 | Buy | +35,064 | $2.12 | $74.34K | 1,166,466 |
| Glen R. Anderson 10% owner | Aug 10, 2023 | Buy | +44,354 | $1.94 | $86.05K | 1,131,402 |
| Boyan Vesselinov Litchev Chief Medical Officer | Dec 1, 2022 | Buy | +500 | $1.87 | $935 | 1,150 |
| Boyan Vesselinov Litchev Chief Medical Officer | Nov 22, 2022 | Buy | +500 | $1.83 | $915 | 650 |
| Jeffrey A. Meckler CEO and Director | Nov 21, 2022 | Buy | +9,600 | $1.90 | $18.24K | 75,374 |
| Jeffrey A. Meckler CEO and Director | Nov 18, 2022 | Buy | +400 | $1.76 | $704 | 65,774 |
| Jeffrey A. Meckler CEO and Director | Sep 8, 2022 | Buy | +10,308 | $2.80 | $28.86K | 65,374 |
| Walt Addison Linscott Chief Business Officer | Sep 7, 2022 | Buy | +150 | $2.62 | $393 | 150 |
| Jeffrey A. Meckler CEO and Director | Sep 7, 2022 | Buy | +8,632 | $2.57 | $22.18K | 55,066 |
| Jeffrey A. Meckler CEO and Director | Sep 6, 2022 | Buy | +1,060 | $2.44 | $2.59K | 46,434 |
| Jeffrey A. Meckler CEO and Director | Jun 6, 2022 | Buy | +19,727 | $2.63 | $51.88K | 45,374 |
| Boyan Vesselinov Litchev Chief Medical Officer | Mar 2, 2022 | Buy | +50 | $4.09 | $205 | 150 |
| Michael James Newman CSO and Director, 10% owner | Feb 1, 2022 | Sale(10b5-1 plan) | −14,130 | $5.00 | $70.65K | 1,368,356 |
| Boyan Vesselinov Litchev Chief Medical Officer | Jan 31, 2022 | Buy | +100 | $4.65 | $465 | 100 |
| Michael James Newman CSO and Director, 10% owner | Jan 31, 2022 | Sale(10b5-1 plan) | −5,870 | $5.00 | $29.35K | 1,382,486 |
| Jeffrey A. Meckler CEO and Director | Nov 18, 2021 | Buy | +11,187 | $5.82 | $65.11K | 25,647 |
| Jeffrey A. Meckler CEO and Director | Sep 14, 2021 | Buy | +12,000 | $7.00 | $84.00K | 14,460 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Indaptus Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 120,693 shares on Sep 10, 2026 over the last 90 days.
See a number that looks wrong?